Free Trial

Skye Bioscience (SKYE) Competitors

Skye Bioscience logo
$1.48 +0.03 (+1.72%)
As of 10:06 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SKYE vs. TNXP, BIOA, SLS, ACRS, PLX, CHRS, DERM, GNFT, IVVD, and MDWD

Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Tonix Pharmaceuticals (TNXP), BioAge Labs (BIOA), SELLAS Life Sciences Group (SLS), Aclaris Therapeutics (ACRS), Protalix BioTherapeutics (PLX), Coherus Oncology (CHRS), Journey Medical (DERM), GENFIT (GNFT), Invivyd (IVVD), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry.

Skye Bioscience vs. Its Competitors

Tonix Pharmaceuticals (NASDAQ:TNXP) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Tonix Pharmaceuticals presently has a consensus price target of $70.00, indicating a potential upside of 271.35%. Skye Bioscience has a consensus price target of $9.80, indicating a potential upside of 564.41%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Tonix Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Skye Bioscience
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57

Skye Bioscience has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -828.22%. Tonix Pharmaceuticals' return on equity of -57.93% beat Skye Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals-828.22% -57.93% -51.04%
Skye Bioscience N/A -76.03%-69.20%

In the previous week, Tonix Pharmaceuticals and Tonix Pharmaceuticals both had 5 articles in the media. Skye Bioscience's average media sentiment score of 0.49 beat Tonix Pharmaceuticals' score of -0.07 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tonix Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Skye Bioscience
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tonix Pharmaceuticals has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.

Skye Bioscience has lower revenue, but higher earnings than Tonix Pharmaceuticals. Skye Bioscience is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tonix Pharmaceuticals$10.09M16.38-$130.04M-$39.47-0.48
Skye BioscienceN/AN/A-$26.57M-$1.06-1.39

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 4.5% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Skye Bioscience beats Tonix Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Skye Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SKYE vs. The Competition

MetricSkye BioscienceMED IndustryMedical SectorNASDAQ Exchange
Market Cap$45.71M$3.42B$6.10B$10.49B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio-1.3923.0484.6327.17
Price / SalesN/A484.44608.51132.45
Price / CashN/A46.9737.8662.13
Price / Book0.6610.5112.356.62
Net Income-$26.57M-$52.47M$3.33B$276.88M
7 Day Performance-14.74%3.06%2.11%1.49%
1 Month Performance-62.28%15.52%9.40%4.79%
1 Year Performance-65.13%13.77%73.46%36.32%

Skye Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SKYE
Skye Bioscience
2.5295 of 5 stars
$1.48
+1.7%
$9.80
+564.4%
-66.1%$45.71MN/A-1.3911
TNXP
Tonix Pharmaceuticals
2.8466 of 5 stars
$23.00
-5.0%
$70.00
+204.3%
+18.3%$201.71M$10.09M-0.5850Short Interest ↑
Gap Down
BIOA
BioAge Labs
0.2621 of 5 stars
$5.60
-0.5%
N/AN/A$200.76MN/A0.00N/APositive News
SLS
SELLAS Life Sciences Group
1.2952 of 5 stars
$1.90
+0.5%
$7.00
+268.4%
+72.8%$200.06MN/A-5.9410Options Volume
ACRS
Aclaris Therapeutics
2.3908 of 5 stars
$1.84
-3.2%
$8.71
+373.6%
+76.7%$199.33M$16.79M-1.34100News Coverage
Analyst Forecast
Analyst Revision
Gap Down
PLX
Protalix BioTherapeutics
1.6912 of 5 stars
$2.50
-3.8%
$15.00
+500.0%
+120.2%$199.33M$61.95M-19.23200News Coverage
High Trading Volume
CHRS
Coherus Oncology
4.189 of 5 stars
$1.71
+0.6%
$4.51
+163.9%
+92.9%$198.75M$266.96M1.10330Positive News
DERM
Journey Medical
1.9951 of 5 stars
$7.55
+3.6%
$12.17
+61.1%
+17.8%$198.64M$56.40M-19.8790
GNFT
GENFIT
2.1103 of 5 stars
$3.96
-1.7%
$7.00
+76.8%
-33.8%$198.01M$41.52M0.00120Positive News
Analyst Forecast
Gap Down
IVVD
Invivyd
3.9363 of 5 stars
$1.63
+14.8%
$5.14
+215.2%
+77.5%$195.83M$25.38M-1.77100Analyst Downgrade
MDWD
MediWound
1.9292 of 5 stars
$17.54
-1.0%
$32.25
+83.9%
+8.3%$194.52M$20.22M-6.6480

Related Companies and Tools


This page (NASDAQ:SKYE) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners